By Karen Bernstein
Editor-in-Chief

By choosing a contract sales organization and constructing an imaginative risk-sharing arrangement, CV Therapeutics Inc. has established a marketing approach for its ranolazine treatment for chronic stable angina that other biotech companies may want to copy. If the numbers work out as planned, this type of marketing arrangement would be far more attractive to most young, single-product biotech companies than either of the conventional alternatives: marketing on their own or finding a pharmaceutical company partner.